Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Other Non-Current Assets (2018 - 2025)

Autolus Therapeutics' Other Non-Current Assets history spans 8 years, with the latest figure at $249000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 74.14% year-over-year to $249000.0; the TTM value through Dec 2025 reached $249000.0, down 74.14%, while the annual FY2025 figure was $249000.0, 74.14% down from the prior year.
  • Other Non-Current Assets reached $249000.0 in Q4 2025 per AUTL's latest filing, up from $191000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $5.3 million in Q2 2025 to a low of $116000.0 in Q1 2025.
  • Average Other Non-Current Assets over 5 years is $1.3 million, with a median of $963000.0 recorded in 2024.
  • The largest YoY upside for Other Non-Current Assets was 1751.41% in 2025 against a maximum downside of 88.1% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $2.4 million in 2021, then decreased by 7.87% to $2.2 million in 2022, then tumbled by 82.54% to $380000.0 in 2023, then surged by 153.42% to $963000.0 in 2024, then tumbled by 74.14% to $249000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Other Non-Current Assets are $249000.0 (Q4 2025), $191000.0 (Q3 2025), and $5.3 million (Q2 2025).